YBX1 and cancer: Mechanistically, we show that aggressiveness of TNBC tumors of AA origin is driven by the YB1-mediated activation of resistance to chemotherapeutic drugs, by activating genes that are associated with the cancer stem cell phenotype and chemoresistance.